Defilade Capital Management L.P. Lowers Holdings in Biogen Inc. $BIIB

Defilade Capital Management L.P. decreased its holdings in Biogen Inc. (NASDAQ:BIIB) by 40.6% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 96,289 shares of the biotechnology company’s stock after selling 65,703 shares during the period. Biogen accounts for about 2.5% of Defilade Capital Management L.P.’s portfolio, making the stock its 20th biggest holding. Defilade Capital Management L.P. owned approximately 0.07% of Biogen worth $17,653,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in BIIB. Reflection Asset Management purchased a new position in Biogen in the 4th quarter worth approximately $25,000. WPG Advisers LLC grew its holdings in Biogen by 417.9% during the 4th quarter. WPG Advisers LLC now owns 145 shares of the biotechnology company’s stock valued at $26,000 after buying an additional 117 shares in the last quarter. First Horizon Corp bought a new stake in shares of Biogen during the fourth quarter valued at approximately $30,000. WFA of San Diego LLC bought a new stake in shares of Biogen during the second quarter valued at approximately $32,000. Finally, Root Financial Partners LLC lifted its holdings in shares of Biogen by 198.4% in the fourth quarter. Root Financial Partners LLC now owns 185 shares of the biotechnology company’s stock worth $33,000 after buying an additional 123 shares in the last quarter. Hedge funds and other institutional investors own 87.93% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on the stock. Rothschild & Co Redburn upped their target price on shares of Biogen from $180.00 to $190.00 in a research report on Thursday, April 30th. Guggenheim lifted their price target on shares of Biogen from $260.00 to $280.00 and gave the company a “buy” rating in a report on Tuesday, July 21st. Oppenheimer reiterated an “outperform” rating and issued a $300.00 price target on shares of Biogen in a research note on Wednesday. Weiss Ratings reissued a “hold (c)” rating on shares of Biogen in a report on Wednesday. Finally, HSBC restated a “reduce” rating and set a $157.00 price objective on shares of Biogen in a research report on Monday, July 6th. One research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating, thirteen have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $223.36.

Key Biogen News

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Biogen reported second-quarter revenue of $2.74 billion, up 3.4% year over year and ahead of consensus estimates of approximately $2.46 billion. Growth was led by newer products and the company’s growth portfolio, helping adjusted EPS reach $3.60 versus the $2.94 analyst estimate. Biogen beats quarterly estimates as newer drugs drive growth
• Positive Sentiment: Management raised its revenue outlook and highlighted continued momentum in newer medicines and strategic acquisitions, supporting the view that Biogen is gradually reducing its reliance on older products. Biogen raises revenue outlook as growth portfolio drives Q2 beat
• Positive Sentiment: Several analysts became more constructive after the results. TD Cowen raised its price target to $225 and upgraded the stock to Buy, while Morgan Stanley increased its target to $231, although it retained an Equal Weight rating. Barclays also expects the shares to rise.
• Neutral Sentiment: Wedbush raised its price target from $201 to $215 but maintained a Neutral rating, and Piper Sandler reaffirmed its Buy rating. Zacks upgraded Biogen from Strong Sell to Hold, indicating improving sentiment but not broad analyst conviction.
• Negative Sentiment: Reported profitability deteriorated substantially. Second-quarter net income fell to $97.5 million, while diluted EPS from continuing operations declined to $0.66 from $4.33 a year earlier; first-half net income also dropped to $417 million from $875.3 million. The sharp gap between revenue growth and reported earnings is raising concerns that profitability may be peaking. Biogen earnings and profitability analysis

Biogen Price Performance

BIIB stock opened at $202.95 on Monday. Biogen Inc. has a 52 week low of $124.56 and a 52 week high of $219.72. The company has a quick ratio of 1.26, a current ratio of 1.87 and a debt-to-equity ratio of 0.39. The company has a fifty day simple moving average of $201.23 and a two-hundred day simple moving average of $190.64. The firm has a market capitalization of $29.99 billion, a P/E ratio of 35.92, a price-to-earnings-growth ratio of 6.20 and a beta of 0.17.

Biogen (NASDAQ:BIIB) last posted its earnings results on Wednesday, July 29th. The biotechnology company reported $3.60 earnings per share for the quarter, topping analysts’ consensus estimates of $2.94 by $0.66. The firm had revenue of $2.74 billion for the quarter, compared to the consensus estimate of $2.46 billion. Biogen had a net margin of 8.32% and a return on equity of 11.18%. The business’s quarterly revenue was up 3.4% on a year-over-year basis. During the same period in the previous year, the firm posted $5.47 EPS. Biogen has set its FY 2026 guidance at 12.000-13.000 EPS. Analysts anticipate that Biogen Inc. will post 12.65 earnings per share for the current fiscal year.

Biogen Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.